Small-molecule BCL6 inhibitor effectively treats mice with nonsclerodermatous chronic graft-versus-host disease

Patient outcomes for steroid-dependent or -refractory chronic graft-versus-host diesease (cGVHD) are poor, and only ibrutinib has been US Food and Drug Administration (FDA) approved for this indication. cGVHD is often driven by the germinal center (GC) reaction, in which T follicular helper cells in...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Blood
Main Authors: Paz, Katelyn, Flynn, Ryan, Du, Jing, Qi, Jun, Luznik, Leo, Maillard, Ivan, MacDonald, Kelli P., Hill, Geoffrey R., Serody, Jonathan S., Murphy, William J., Sage, Peter T., Sharpe, Arlene H., Miklos, David, Cutler, Corey S., Koreth, John, Antin, Joseph H., Soiffer, Robert J., Ritz, Jerome, Bradner, James E., Melnick, Ari M., Blazar, Bruce R.
Formato: Artigo
Idioma:Inglês
Publicado em: American Society of Hematology 2019
Assuntos:
Transplantation
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC6318432/
https://ncbi.nlm.nih.gov/pubmed/30279226
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/blood-2018-03-839993
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados